The investigation launched with the Competition Board decision dated 13.04.2023 and numbered 23-18/343-M(8) on Haks Hamzaoğlu Kimya San. ve Tic. AŞ (Haks Kimya), which produces and sells food supplements, baby formula, cosmetics and medical products under various brands such Nurse Harvey’s and Gifrer, was completed with the submission of Haks Kimya’s third written plea on 31.05.2024, and thus reached the hearing stage. The hearing will be held at the Competition Authority Headquarters on July 23, 2024, at 14:30.
The investigation was launched to determine if Haks Kimya violated Article 4 of the Act no 4054 on the Protection of Competition by fixing the resale prices of its buyers.
The investigation examined the following allegations:

• Internet sale prices and, in particular, e-commerce platforms of the buyers were closely monitored, 
• Efforts were made to ensure that buyers complied with the set/notified list prices and/or discount rates and did not sell products for less than the set price,
• The buyers were warned that sanction mechanisms, including the termination of supply and/or business relationship would be applied if the buyers did not comply with the sale prices set, 
• The behavior concerned constituted direct intervention in the pricing freedom of the buyers.